Optiscan is proud to be featured in Stockhead for its innovative platform addressing the global pathologist shortage. The article discusses how Optiscan’s real-time digital pathology technology streamlines workflows for pathologists, enabling faster, more accurate diagnoses.

This technology is particularly impactful during surgeries for identifying malignant tumors and pre-cancerous lesions, reducing the need for additional procedures. CEO Dr. Camile Farah highlights the potential of Optiscan's platform to revolutionize pathology and cancer treatment.

Read the full article here.